1 The haematological side-effects of mianserin have been studied. 2 There are 26 reported cases, of which 19 appear to show a definite association with the drug. A high proportion are female. 3 A reversible agranulocytosis has been most commonly observed, occurring between four and six weeks of treatment. On cessation of therapy, the counts have recovered. 4 Three patients have died, following a longer course of treatment. Two of these were septicaemic and the third, thrombocytopenic in addition. This is probably related to a failure of marrow recovery owing to the longer exposure, in the third case progressing to aplasia. 5 The number of reported dyscrasias is extremely small compared with the number of courses of mianserin prescribed. 6 It is desirable that a blood examination should be made at four weeks after starting treatment with mianserin to identify those patients at risk.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1427906 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.1983.tb05877.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.
Front Pharmacol
October 2024
Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland.
Aim: Our objective was to systematically assess the prevalence and clinical features of adverse events related to interactions between cannabinoids and psychotropic drugs through a retrospective chart review.
Methodology: 1586 adverse event reports were assessed. Cases included in the analysis showed a high probability of a causal relationships between cannabinoid-psychotropic drug interactions and adverse events.
Imagery rehearsal therapy and mianserin for trauma-affected refugees: Follow-up of a randomized controlled trial.
Torture
October 2024
Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. Correspondence to:
Introduction: In order to identify the efficacy of treatment interventions for trauma-affected refugees follow-up studies are highly warranted. Hence, the overall aim of this study was to examine the effi-cacy of sleep-enhancing treatment, IRT and mianserin, in a sample of 219 trauma-affected refugees at six-month follow-up post-treatment.
Methods: Data were derived from a four-armed randomized controlled trial in a sample of trauma-affected refugees with PTSD.
Brain-derived neurotrophic factor modulation in response to oxidative stress and corticosterone: role of scopolamine and mirtazapine.
Life Sci
December 2024
OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal; CINTESIS@RISE, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal; Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal. Electronic address:
Unlabelled: Major Depressive Disorder (MDD) is a very complex disease, challenging to study and manage. The complexities of MDD require extensive research of its mechanisms to develop more effective therapeutic approaches. Crucial in the context of this disease is the role of brain-derived neurotrophic factor (BDNF) signaling pathway.
View Article and Find Full Text PDFCombination of low-dose, long-term immunoglobulin and mirtazapine is effective in progressive multifocal leukoencephalopathy caused by JC virus infection.
BMC Neurol
October 2024
Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.
Article Synopsis
- Progressive multifocal leukoencephalopathy (PML) is a severe brain disease caused by the John Cunningham Virus (JCV), with no widely accepted antiviral treatment available.
- A case study reports a patient with previous immunosuppressive therapy for dermatomyositis, who was diagnosed with PML and treated with a combination of low-dose immunoglobulin and mirtazapine, leading to significant clinical improvement and a decrease in JCV levels to zero after four months.
- This findings suggest that this combined treatment approach may effectively regulate the immune response and control the progression of PML, presenting a potential new therapy option.
[Not Available].
MMW Fortschr Med
October 2024
Springer Medizin Verlag GmbH, Aschauer Straße 30, 81549, München, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!